CLEAR Autism Diagnostic Evaluation (CADE): Evaluation of Reliability and Validity

Area of Science:

• Neurodevelopmental Disorders
• Clinical Psychology
• Psychometrics

Background:

• Autism Spectrum Disorder (ASD) affects 1 in 54 U.S. children, representing a significant public health concern.
• Despite early diagnostic markers at 24 months, the median age for ASD diagnosis in the U.S. remains high at 51 months.
• The CLEAR Autism Diagnostic Evaluation (CADE) was developed to streamline and standardize the ASD evaluation process.

Purpose of the Study:

• To examine the reliability and validity of the CADE scale.
• To assess the CADE's effectiveness in a clinical setting for ASD evaluation.
• To determine if the CADE can improve the timeliness and accuracy of ASD diagnosis.

Main Methods:

• The CADE, a 33-item caregiver and clinician rating scale, was administered to 191 individuals undergoing private ASD evaluations.
• Clinicians completed CADE items using client evaluation records.
• Internal consistency, correlation with ADOS scores, and diagnostic accuracy were analyzed.

Main Results:

• The CADE demonstrated high internal consistency with a coefficient alpha of .94.
• CADE total scores showed strong correlations with ADOS scores (r = .52-.86).
• The CADE accurately discriminated between individuals with and without ASD (p < .001) with excellent diagnostic accuracy (ROC AUC = .998).

Conclusions:

• The CADE is a reliable and valid instrument for ASD evaluation.
• The CADE provides an efficient and accurate method for assessing Autism Spectrum Disorder.
• Findings support the CADE's potential to improve early ASD identification and diagnosis.